Arthritis News

Latest Arthritis News From Medical News Today.

Total news: 28
Last news: August 23, 2007 22:00:00

Thousands of adults with severe rheumatoid arthritis may now have their hopes of returning to full social and working life realised, thanks to a NICE decision hailed as a triumph by the leading arthritis-voice organisation. [click link for full article] - [Read more]

The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of rituximab (Mabthera) for the treatment of rheumatoid arthritis and adalimumab (Humira) for the treatment of psoriatic arthritis, as part of its rapid single technology appraisal (STA) work programme. [click link for full article] - [Read more]

DePuy Orthopaedics, Inc., announced an advancement in online education for the more than 200,000 Americans who undergo hip replacement each year.1 This extensive patient Web site, http://www.hipreplacement.com, provides hip pain patients with a broad range of resources from mobility assessment tools to surgical options and recovery information, as well as linking to an online discussion group for peer-to-peer support. [click link for full article] - [Read more]

Interleukin Genetics, Inc. (Amex: ILI) announced today that it has initiated a study on the genetics of osteoarthritis in collaboration with Dr. Steven Abramson, Director of the Division of Rheumatology at the Hospital for Joint Diseases of New York University Medical Center. Osteoarthritis (OA) is the breakdown of the cartilage cushion in one or more joints of the body leading to pain, to limitation in movement, and in many cases to joint replacement. [click link for full article] - [Read more]

In an Editorial, to be published in the international journal Osteoarthritis and Cartilage (http://intl.elsevierhealth.com/journals/joca/), published by Elsevier, a panel of arthritis research experts has recommended that coxibs and nonsteroidal anti-inflammatory drugs (NSAIDs) must remain a significant part of the tool kit used in treating osteoarthritis (OA). [click link for full article] - [Read more]

After discussion with the US Food and Drug Administration (FDA) a drug manufacturer has halted a gene therapy trial of a new experimental drug to treat inflammatory arthritis because a woman who was taking part in the trial has died. 28 other trials using the same type of gene therapy are also being investigated according to the Associated Press. [click link for full article] - [Read more]

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the supplemental biologics license application (sBLA) for ORENCIA® (abatacept) for the treatment of pediatric patients with juvenile idiopathic arthritis (JIA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists. [click link for full article] - [Read more]

Glycine is a non-essential amino acid used by an organism to synthesise proteins and is present in foods such as fish, meat or dairy products. [click link for full article] - [Read more]

When a wrist hurts, it could be carpal tunnel syndrome -- or something else. Over time, many conditions can affect crucial parts of the hands, causing everything from pain to the loss of normal function. The August issue of Mayo Clinic Womens HealthSource offers an overview of common hand conditions and treatments:Thumb arthritis: This occurs when the joint at the wrist and base of the thumb develops osteoarthritis. Its more common after age 40. [click link for full article] - [Read more]

Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the supplemental biologics license application (sBLA) for ORENCIA (abatacept) for the treatment of pediatric patients with juvenile idiopathic arthritis (JIA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists. [click link for full article] - [Read more]

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the supplemental biologics license application (sBLA) for ORENCIA(R) (abatacept) for the treatment of pediatric patients with juvenile idiopathic arthritis (JIA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists. [click link for full article] - [Read more]

The worlds most common joint disease, osteoarthritis (OA) affects more than 10 percent of American adults, nearly 80 percent of people past age 55, and about three times as many women as men. Treatment has been targeted at controlling the pain that tends to come with the progressive loss of articular cartilage cushioning the joints, disintegration of the underlying bone, and the formation of bone spurs or osteophytes. [click link for full article] - [Read more]

Researchers and clinicians have widely noted an intriguing link between some intestinal diseases and some forms of arthritis. In particular, chronic inflammatory bowel disease (IBD) frequently afflicts patients with ankylosing spondylitis (AS), marked by chronic inflammation of the spine and the sacroiliac joints. Separately, both IBD and AS have been shown to run in families. Yet, the specific genetic susceptibility, and whether it is the same for both diseases, remains a mystery. [click link for full article] - [Read more]

Arthritis is common among elderly Americans, and as the population ages it is expected to increase. At the same time, disability is increasing in patients with arthritis and the racial/ethnic composition of the U.S. is changing; minority populations are forecasted to increase from 30.6 percent of the population in 2000 to 49.9 percent by 2050. A new study published in the August issue of [click link for full article] - [Read more]

A new investigational anti-inflammatory drug has produced promising results in scientific animal studies as an arthritis control therapy. The new drug is a proprietary compound developed by Australian biotechnology company Novogen Limited (Nasdaq: NVGN; ASX: NRT) from its phenolic technology platform. [click link for full article] - [Read more]

Roche has announced that results from the AMBITION (Actemra versus Methotrexate double-Blind Investigative Trial In mONotherapy) trial, the fourth multinational Phase III study of ACTEMRA(TM), not only successfully met its primary endpoint of non-inferiority in patients with moderate to severe rheumatoid arthritis (RA), but also demonstrated superiority over the standard effective dose regimen of methotrexate alone. [click link for full article] - [Read more]

People who have diets with plenty of foods containing antioxidants may be protecting themselves from bone changes associated with knee arthritis, according to a new study. Australian researchers found that middle-aged adults with higher dietary levels of vitamin C were less likely to develop certain bone abnormalities that contribute to knee arthritis. [click link for full article] - [Read more]

The factors associated with poor short-term recovery from knee surgery appear to be different than those found to mar long-term outcome from the same surgery, according to new research released at the 2007 Annual Meeting of the American Orthopaedic Society for Sports Medicine at the Telus Convention Center. [click link for full article] - [Read more]

Far fewer rheumatoid arthritis patients treated with the drug hydroxychloroquine (HCQ) went on to develop diabetes compared to those who never took the drug, according to a 20-plus-year University of Pittsburgh School of Medicine-led study reported in the Journal of the American Medical Association. In addition, those using HCQ who did develop diabetes were less likely to take medications to manage their disease after diagnosis. [click link for full article] - [Read more]

Rheumatoid arthritis (RA) affects 2.1 million Americans and despite many advances in the understanding of the disease, funds for research remain limited and both the cause and a cure are still unknown. The American College of Rheumatology Research and Education Foundation (ACR REF) is working to accelerate RA research and expand financial support of this disease by launching the Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign. [click link for full article] - [Read more]